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Abstract
Background: Pulmonary arterial hypertension consists in an increase of mean pulmonary arterial pressure (PAPm 25mmHg),
and may lead to right ventricular failure. Pulmonary arterial hypertension can arise in several disorders, encompassing inflammatory
conditions and connective tissue diseases. The occurrence of pulmonary arterial hypertension has recently been reported in
monogenic interferonopathies and in systemic lupus erythematosus, highlighting the pathogenic role of type I interferons and
paving the way to therapies aimed at inhibiting interferon signaling.
Case: We describe a 17-year-old boy with DNase II deficiency, presenting a clinical picture with significant overlap with systemic
lupus erythematosus. During treatment with the Janus kinase inhibitor ruxolitinib, he developed pulmonary arterial hypertension,
raising the question whether it could represent a sign of insufficient disease control or a drug-related adverse event. The disease
even worsened after drug withdrawal, but rapidly improved after starting the drug again at higher dosage.
Summary and conclusion: Pulmonary arterial hypertension can complicate type I interferonopathies. We propose that rux-
olitinib was beneficial in this case, but the wider role of Janus kinase inhibitors for the treatment of pulmonary arterial hypertension
is not clear. For this reason, a strict cardiologic evaluation must be part of the standard care of subjects with interferonopathies,
especially when Janus kinase inhibitors are prescribed.
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Introduction
Interferonopathies are a group of disorders characterized
by genetically determined imbalance in type-1 interferon
inﬂammation and by a signiﬁcant clinical overlap with sys-
temic lupus erythematous.1 Patients with interferonopathies
(SLE), may develop complications in the lungs including
pulmonary arterial hypertension (PAH).2
Pre-capillary pulmonary arterial hypertension is deﬁned
by the elevation of mean pulmonary arterial pressure at rest
(mPAP 25mmHg), with normal pulmonary arterial wedge
pressure. Although a wide range of underlying causes can
lead to this condition, in many cases, the pathogenesis
remains unclear.3
We report a case of PAH in a 17-year-old boy with
monogenic interferonopathy and systemic lupus erythema-
tosus (SLE)-like features due to DNase II deﬁciency, treated
with the Janus kinase inhibitor ruxolitinib to modulate
interferon signaling.
Case description
A 17-year-old boy was admitted to our hospital for weak-
ness, palpitations and dyspnea. All symptoms were
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exacerbated by minimal eﬀort, and syncope was provoked
by an argument with his father. Physical examination
revealed paleness, cold extremities, accentuated second
heart sound and a pansystolic heart murmur. The patient
was in a follow-up program for DNase II deﬁciency syn-
drome,4 a recently described auto-inﬂammatory disorder
with signiﬁcant overlap with SLE. One month before, he
had a likely viral illness accompanied by tachycardia and
general discomfort, self-improving in the following days.
His medical history was characterized by the presence of
neonatal hepatopathy, cytopenia, recurrent fever, polyarti-
cular arthritis, chronic glomerulonephritis, lipodystrophy,
lupus pernio and growth retardation. The suspicion of an
interferonopathy was raised at the age of 14 years, based on
the detection of an extremely high interferon signature
score, and the diagnosis of DNase II deﬁciency was made
by whole exome sequencing soon after. This clinical picture
progressively worsened in the following years despite several
therapeutic trials with glucocorticoids, immunosuppressant
and biological agents. Considering recent data in support of
a direct inhibitory eﬀect of hydroxychloroquine and mepa-
crine on the signaling cascade of type 1 interferons,5 we
added these two antimalarials to therapy, noticing a partial
improvement in the general assessment of the disease
(Fig. 1). Due to concern about ongoing arthritis and given
the poor response to anti-TNF biologics, we added abata-
cept. Despite signiﬁcant improvements, the boy remained
dependent on chronic glucocorticoids, complaining of joint
stiﬀness and severe headache. We thus proposed an oﬀ-label
use of ruxolitinib (7.5mg twice a day), a Janus kinase inhibi-
tor that had just been used with success in another interfer-
onopathy6 and discontinued abatacept. The introduction of
ruxolitinib led to a dramatic improvement of the patient’s
clinical manifestations, allowing progressively reduce the
dosage of glucocorticoids (Fig. 1).
At admission, ﬁve months after ruxolitinib introduction,
echocardiography showed severe pulmonary hypertension
with systolic PAP 77mmHg and severe right ventricular
dysfunction. Data were conﬁrmed by cardiac catheterization
that showed severe pre-capillary PAH with reduced
cardiac index and a negative vasoreactivity test (PAP
82/49/61mmHg, PAWP 11mmHg, PVR 21.5 WU, CI
1.8L/min/m2, data acquired under profound sedation).
Pulmonary embolism was excluded by a normal CT pul-
monary angiogram. Being the cardiologic evaluation with
echocardiogram and electrocardiogram performed one
year before completely normal, a drug-related serious
adverse eﬀect was considered, and all the treatments were
discontinued. Conversely, assuming the possibility that
PAH was instead an inﬂammatory manifestation of the
underlying disease, similarly to what can sometimes occur
in SLE, possibly triggered by a recent viral illness as
occurred one month before in our patient, steroid boluses
were administered, and a vasodilating therapy with epopros-
tenol, sildenaﬁl and furosemide was started. However,
during the hospital course, the boy developed a severe multi-
linear pancytopenia (Hb 10 g/dl, WBC 1020/mmc, PLT
20,000/mmc). Hemophagocytic Lymphohistiocytosis and
malignancy were ruled out after performing a bone
marrow aspiration that showed a hypocellular situation.
Interferon signature score was higher than ever (Fig. 1).
An active viral infection was also excluded. Given the
poor response to corticosteroids and the raised interferon
score, ruxolitinib was reintroduced at higher doses (10mg
twice daily), based on the previous beneﬁts and on anecdotal
evidence of eﬃcacy in PAH.7 A dramatic improvement of
his pulmonary pressure recorded by echocardiogram was
noted in just a day, being much more successful than expect-
able with vasodilating therapy only. The patient was dis-
charged on inhaled iloprost 5 mg every 4 h, daily
Fig. 1. Interferon signature trend in the reported clinical case. IS-1: before starting Ruxolitinib; IS-2: in Ruxolitinib-before PAH; IS-3: during PAH.
IS-4: after increasing ruxolitinib. The error bars reflect technical variability.
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ambrisentan 5mg, sildenaﬁl 60mg in three daily doses, and
furosemide 12.5mg every two days (Fig. 1), with an esti-
mated systolic pulmonary pressure of 35mmHg at echocar-
diography. His cardiologic follow-up showed a slow but
progressive further improvement of symptoms and pulmon-
ary pressure. Ruxolitinib was maintained at the dose of
7.5mg BID. No further adverse event was noticed in the
following two years, apart from asymptomatic BK-viruria
and a transient herpes zoster infection, which rapidly healed
with acyclovir therapy and slightly reducing ruxolitinib dose
for one week.
Discussion
Type I interferon inﬂammation can aﬀect a wide range of
organs and tissues. Pulmonary hypertension has been
described in primary interferonopathies such as in STING
associated vasculopathy with onset in infancy,8 chronic
atypical neutrophilic dermatosis with lipodystrophy and ele-
vated temperature9 and in Aicardi-Goutie`res syndrome.10
We report for the ﬁrst time the presence of PAH in
DNase II deﬁciency. The role that ruxolitinib played in
our case is uncertain. On one hand, a previous report cau-
tioned us about the possible worsening of ruxolitinib on
PAH in a patient with myeloﬁbrosis,11 despite the evidence
of eﬃcacy of this drug in the treatment of myeloﬁbrosis-
associated PAH in larger series.7
On the other hand, the occurrence of PAH in our patient
seemed unlikely to represent an adverse event caused by
ruxolitinib, as we observed a rebound-inﬂammation with
increased interferon score after stopping ruxolitinib, as pre-
viously reported in other interpheronopaties,6 without any
improvement on mPAP, despite the start of vasodilators for
a week. Conversely, a dramatic drop in mPAP was recorded
the day after re-starting ruxolitinib at higher dosage,
together with a reduction of the interferon score in the fol-
lowing days. Moreover, there are several evidence support-
ing a possible role of JAK inhibitors in the treatment of
PAH.6 First, JAK2-inhibitors can reduce the proliferation
of pulmonary arterial endothelial cells in idiopathic PAH.12
Second, the beneﬁcial action of JAK2-inhibitors in PAH has
been related to increased release of NO in animal models,7
although it is uncertain if this was the mechanism in our
clinical case, as the vasoreactivity test was negative.
Third, PAH has been associated to elevated interferon
signature, in particular in the early phases of development13
and can be induced by therapeutic administration of inter-
ferons in various disorders.14
We cannot be sure that the improvement noticed in our
case was due to the addition of ruxolitinib; however, the
rapid response to treatments supports a major role of
inﬂammatory factors rather than vascular remodeling in
our case.
In fact, it can be hard to disentangle between manifest-
ations of the disease and the eﬀects of treatments tailored to
each patient without a consistent previous experience, as is
evident for orphan diseases. Moreover, JAK inhibitors may
favor the development of viral illnesses that can contribute
to trigger PAH in susceptible individuals. Even if we failed
to detect speciﬁc viruses, we cannot exclude that a previous
infection could have triggered the development of PAH one
month before.
A recent study showed that subjects with monogenic
interferonopathies can be treated with the JAK inhibitor
baricitinib at twice-higher dosages than those used in
rheumatoid arthritis, without complete suppression of the
interferon signaling and with acceptable safety proﬁle.10
Similarly, even if our patient developed a herpes zoster
during the ruxolitinib therapy, the outcome of the infection
was favorable without the need of discontinuing the drug.
In conclusion, we highlight the necessity to refer patients
with primary interferonopathy to a pediatric cardiologist for
scheduled evaluations with echocardiography, in particular
when prescribing new treatments.
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